Mathew Lin

TMET-27. Mutant IDH silences GSX2 to reprogram neural progenitor cell fate and promote gliomagenesis

Yi Xiao, Diana D. Shi, Ethan Neumann, Michael M. Levitt et autres

Abstract Isocitrate dehydrogenase (IDH) gene mutations occur early among the genetic alterations that lead to the formation of lower-grade adult-type diffuse gliomas. Mutant IDH enzymes synthesize the oncometabolite (R)-2-hydroxyglutarate (2HG), which inhibits α-ketoglutarate-dependent dioxygenases, including those involved in DNA and histonedemethylation. Although …

us, il (code pays fourni par la source)

TMOD-12. Preclinical and clinical assessment of chemoradiation after mutant IDH inhibitor treatment in IDH-mutant glioma

Diana D. Shi, Ester Calvo-Fernández, Vineshkumar Thidil Puliyappadamba, Tyler Ashford Lanman et autres

Abstract BACKGROUND The efficacy of radiation (RT) and chemotherapy after mutant IDH inhibitors (mIDHi) in IDH-mutant glioma is increasingly relevant, but challenging to address due to limited clinical data and lack of mIDHi-responsive preclinical glioma models. METHODS First, we identified clinical outcomes …

us, fr (code pays fourni par la source)

Remission of TP53 -Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)

Guenther Koehne, Muhammad Umair Mushtaq, Lori S. Muffly, Manuel Menes et autres

us, ca (code pays fourni par la source)

Mutant IDH silences GSX2 to reprogram neural progenitor cell fate and promote gliomagenesis

Yi Xiao, Diana D. Shi, Ethan Neumann, Michael M. Levitt et autres

Abstract Isocitrate dehydrogenase ( IDH ) mutations arise early in gliomas and are associated with a defined neurodevelopmental cancer cell hierarchy. However, how mutant IDH contributes to this hierarchy and whether this interaction promotes gliomagenesis remain unclear. We captured the dynamics of …

us, Nigéria, il (code pays fourni par la source)

P1429: MULTIPLEX DELETION OF MYELOID ANTIGENS CD33 AND CLL-1 BY CRISPR/CAS9 IN HUMAN HEMATOPOIETIC STEM CELLS HIGHLIGHTS THE POTENTIAL OF NEXT-GENERATION TRANSPLANTS FOR AML TREATMENT.

J. Xavier-Ferrucio, C. Luo, G. Angelini, Srinivasan Krishnamurthy et autres

Background: Acute myeloid leukemia (AML) is a heterogeneous disease characterized by abnormal clonal expansion and is the most common form of adult acute leukemia. Though hematopoietic stem cell transplant is the standard of care for high-risk AML patients, relapse post-transplantation occurs in …

The NOTCH pathway contributes to cell fate decision in myelopoiesis

Laurence Bugeon, Harriet B. Taylor, Fränze Progatzky, Mathew Lin et autres

BACKGROUND: Controversy persists regarding the role of Notch signaling in myelopoiesis. We have used genetic approaches, employing two Notch zebrafish mutants deadly seven (DES) and beamter (BEA) with disrupted function of notch1a and deltaC, respectively, and Notch1a morphants to analyze the development …

gb, us (code pays fourni par la source)